Xenazine, illustration of tablet form (not a photo of the actual pack)

Illustrative image.

Xenazine

Tetrabenazine

Prescription required

$600.00

25mg · 2 × 112 tablets · 3 months supply

BrandBranded medicine

$200.00 per month

How long a supply?

3 months$200.00 a month
6 months$250.00 a month
Supplied from UK

Test mode: no payment is taken. View cart

Annual cost

$3000a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningDepression and suicidality

XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Anyone considering the use of XENAZINE must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician.

Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington's disease. XENAZINE is contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression.

Increases the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease

Balance risks of depression and suicidality with the clinical need for control of chorea when considering the use of XENAZINE

Monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior

Inform patients, caregivers and families of the risk of depression and suicidality and instruct to report behaviors of concern promptly to the treating physician

Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation

Read this with the rest of the clinical information

About Xenazine

Overview

Xenazine contains tetrabenazine and is taken by mouth as a tablet. It is used to treat chorea associated with Huntington’s disease. Its exact effect on chorea is not fully understood, but it is thought to work by blocking a transporter called VMAT2, reducing stores of certain chemical messengers, including dopamine, in nerve endings.

What it treats

Chorea associated with Huntington’s disease.

Safety information

Side effects

Common side effects of Xenazine include sleepiness or sedation, fatigue, difficulty sleeping, depression, restlessness or an inability to sit still (akathisia), anxiety or worsening anxiety, and nausea. Sleepiness may impair your ability to drive or operate complex machinery. Contact a doctor promptly for new or worsening depression, agitation, restlessness, muscle stiffness or Parkinson-like symptoms, or worsening thinking or ability to carry out daily activities. Seek urgent medical help for suicidal thoughts or behaviour. Other serious side effects listed in the label include neuroleptic malignant syndrome (NMS), changes in the heart’s electrical activity called QTc prolongation, low blood pressure, including when standing up, and increased levels of the hormone prolactin. These also warrant medical attention.

FDA boxed warning

Depression and suicidality

XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Anyone considering the use of XENAZINE must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician.

Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington's disease. XENAZINE is contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression.

Increases the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease

Balance risks of depression and suicidality with the clinical need for control of chorea when considering the use of XENAZINE

Monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior

Inform patients, caregivers and families of the risk of depression and suicidality and instruct to report behaviors of concern promptly to the treating physician

Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for thoughts of suicide or suicidal behavior. - Call your doctor right away for new or worsening depression or unusual changes in behavior. - Call your doctor right away for new or worsening agitation, restlessness, difficulty staying still or muscle stiffness.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Xenazine if you are actively suicidal, have untreated or inadequately treated depression, or have liver impairment. Do not take it with deutetrabenazine, valbenazine, monoamine oxidase inhibitors (MAOIs) or reserpine. At least 14 days must pass after stopping an MAOI, and at least 20 days after stopping reserpine, before starting Xenazine. Treatment needs regular review for worsening mood, thinking ability, muscle stiffness or ability to carry out daily activities. Restlessness, agitation, an inability to sit still or Parkinson-like symptoms may require a treatment change. Xenazine must be stopped if neuroleptic malignant syndrome occurs. Strong CYP2D6 inhibitors, such as fluoxetine and paroxetine, require prescribing precautions. Combining Xenazine with other medicines that prolong the heart’s QT interval is not recommended. Sleepiness or sedation may impair driving or operating complex machinery. During pregnancy, Xenazine may harm the unborn baby, based on animal studies.

Using Xenazine

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label XENAZINE (TETRABENAZINE) TABLET [LUNDBECK PHARMACEUTICALS LLC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines